PFS and OS based on response at 3 months. (A) PFS according to BCR-ABL transcript levels at 3 months. Among patients receiving dasatinib, 48%, 37%, and 16% achieved BCR-ABL transcript levels ≤1%, >1% to 10%, and >10% at 3 months, respectively. Among patients receiving imatinib, the percentages were 13%, 51%, and 36%, respectively. Four patients (2 in each treatment arm) progressed before the 3-month molecular landmark and were not included in this analysis. (B) OS according to BCR-ABL transcript levels at 3 months. (C) PFS according to cytogenetic response at 3 months. Among patients receiving dasatinib, 67%, 15%, and 19% achieved CCyR, PCyR, and less than PCyR at 3 months, respectively. Among patients receiving imatinib, the percentages were 36%, 31%, and 33%, respectively. In all panels, patients with response data at 3 months and outcome data after 3 months were included in the analysis.